9 stories mentioning ORKAUpdated 30d ago
Every FINWIRES story that references ORKA, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Paul T Quinlan, General Counsel, on August 14, 2026, sold 52,000 shares in Oruka Therapeutics (ORKA) for $5,641,409. Following the Form 4 filing with the SEC, Quinlan has control over a total of 31,034 common shares of the company, with 31,034 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/907654/000090765426000077/xslF345X05/form4.xml
Arjun Agarwal, Senior Vice President, Finance, on August 13, 2026, sold 10,000 shares in Oruka Therapeutics (ORKA) for $1,066,572. Following the Form 4 filing with the SEC, Agarwal has control over a total of 15,312 common shares of the company, with 15,312 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/907654/000090765426000075/xslF345X05/form4.xml
Arjun Agarwal, Senior Vice President, Finance, on July 13, 2026, sold 9,999 shares in Oruka Therapeutics (ORKA) for $846,180. Following the Form 4 filing with the SEC, Agarwal has control over a total of 15,312 common shares of the company, with 15,312 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/907654/000090765426000071/xslF345X05/form4.xml
Laura Lee Sandler, Chief Operating Officer, on July 01, 2026, sold 5,000 shares in Oruka Therapeutics (ORKA) for $472,079. Following the Form 4 filing with the SEC, Sandler has control over a total of 236,384 common shares of the company, with 236,384 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/907654/000090765426000069/xslF345X05/form4.xml
Oruka Therapeutics (ORKA) could further de-risk its lead psoriasis drug candidate, ORKA-001, with H2 data expected to show stronger 28-week efficacy than its earlier results and AbbVie's (ABBV) Skyrizi, UBS Securities said in a Wednesday note.The firm said psoriasis treatments typically show improving efficacy over time. It expects ORKA-001's PASI100 response rate to increase from about 63% at week 16 to 70% to 80% at week 28.UBS said initial one-year durability data should provide an early indication of ORKA-001's potential for six-month or annual dosing. The firm expects the update in late Q3 or Q4, giving the company more time to include one-year data from additional patients.The investment firm also said AbbVie's planned acquisition of Apogee Therapeutics (APGE) validates the underlying YTE platform used by ORKA-001 and eases concerns about the intellectual property landscape.UBS maintained its buy rating on Oruka and raised its price target to $130 from $100.Price: $94.44, Change: $-0.73, Percent Change: -0.77%
Oruka Therapeutics (ORKA) has an average rating of buy and mean price target of $141.31, according to analysts polled by FactSet.Price: $95.05, Change: $-0.12, Percent Change: -0.13%
Halozyme (HALO) said Wednesday its Hypercon unit entered into an agreement with Oruka Therapeutics (ORKA) on exclusive rights to use a specialized microparticle drug platform for an experimental psoriasis treatment and up to one additional target.The transaction requires an immediate upfront payment, potential future milestone payments, and ongoing mid-single-digit royalties based on future commercial product sales, the company said.The system allows biologic drugs to be more highly concentrated, shrinking the required injection volume and making dosing easier, Halozyme said.Price: $66.17, Change: $+0.30, Percent Change: +0.46%
Laura Lee Sandler, Chief Operating Officer, on May 01, 2026, sold 5,000 shares in Oruka Therapeutics (ORKA) for $319,384. Following the Form 4 filing with the SEC, Sandler has control over a total of 236,984 common shares of the company, with 236,984 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/907654/000090765426000037/xslF345X05/form4.xml
Health care stocks were edging higher pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2% and the iShares Biotechnology ETF (IBB) marginally advancing.Organon (OGN) has agreed to be acquired by Sun Pharmaceutical Industries for $14 per share in an all-cash deal with an $11.75 billion enterprise valuation, the companies said. Shares of Organon were up more than 17% premarket.Oruka Therapeutics (ORKA) stock was up more than 34% after the company said 63.5% of patients treated with ORKA-001 achieved the primary endpoint of complete skin clearance at week 16 in a phase 2a trial in moderate-to-severe plaque psoriasis.Ligand Pharmaceuticals (LGND) shares were up more than 3% after the company said it has agreed to purchase biotechnology peer Xoma Royalty (XOMA) in an all-cash deal valued at roughly $739 million.
